Oversight
Independent governance, impartial decisions and continuing review for bodies assessing GMPs, GDP and supplier-assurance activities.
Explore oversight →WEO Life Sciences
Industry-informed governance, qualified auditors and consistent oversight for voluntary GMPs, GDP and Life Sciences supplier-assurance activities.
Life Sciences
Independent governance, impartial decisions and continuing review for bodies assessing GMPs, GDP and supplier-assurance activities.
Explore oversight →Published recognition criteria and GMPs / GDP auditor competence requirements connect governance, evidence and technical practice.
View framework & recognition →GMPs & GDP auditor competence (PDF) →Pharmaceutical distribution, manufacturing, excipients, cosmetics and related supplier-assurance activities, within the approved program scope.
View standards & technical references →Why WEO?
WEO addresses gaps in oversight and non-regulated or privately operated certification and supplier-assurance activities by defining transparent competence, governance and public-verification requirements.
Structured oversight requirements designed to remain separate from commercial audit delivery and individual recognition interests.
Consistent expectations for supplier audits across pharmaceutical, cosmetic, ingredient, packaging and distribution supply chains.
Framework development informed by qualified industry experts and practical supply-chain risk priorities.
Global Oversight & Supplier Integrity
Life Sciences quality failures can affect product quality, consumer health and patient safety. Yet not every GMPs or GDP activity is supported by the same accreditation, scheme-owner or independent competence-oversight structure.
Defined governance, competence, impartiality, audit-integrity and technical-scope expectations for bodies participating in WEO Life Sciences programs.
Scope-specific qualification and recognition of auditors and lead auditors against defined GMPs and GDP technical programs.
A common assurance architecture supporting more consistent supplier qualification and evaluation across critical supply chains.
Recognized status is searchable in a dedicated Life Sciences Public Registry for organizations and individual professionals.
Technical Scope — Life Sciences
The first WEO Life Sciences programs focus on established GMPs and GDP frameworks relevant to pharmaceutical ingredients, excipients, cosmetics, primary packaging and pharmaceutical distribution.
Standards, frameworks & rules
The existing GMPs and GDP programs remain the initial focus. The wider catalogue also identifies related pharmaceutical, packaging, medical-device and laboratory references; these additional fields require a separately evaluated and agreed scope.
Good manufacturing practice for active pharmaceutical ingredients.
Quality risk management and pharmaceutical quality systems.
Parts I and II and relevant annexes, including Annex 1 and Annex 11 where applicable.
Guide to Good Manufacturing Practice for Medicinal Products; applicable national regulatory requirements take precedence.
Drug manufacturing requirements; Part 11 applies where relevant to electronic records and signatures.
Good manufacturing practice guidance for pharmaceutical excipients.
Pharmaceutical excipient manufacturing and distribution; EXCiPACT approval and scheme requirements remain separate.
Good manufacturing practices for pharmaceutical excipients.
Good manufacturing practice for cosmetic ingredients; scheme-owner requirements apply.
Good manufacturing practices for cosmetic products.
Good distribution practice for medicinal products for human use.
Good storage and distribution practices for medical products.
Distribution of active substances for medicinal products for human use.
Primary packaging materials for medicinal products: ISO 9001 application with GMP requirements.
Medical-device quality management and risk management; additional technical scope requiring separate competence evaluation.
Competence of testing and calibration laboratories.
Published WEO qualification requirements for defined Life Sciences auditor scopes.
Founding Industry Council
WEO is establishing a Founding Industry Council for organizations that want to contribute technical input, supplier-assurance priorities and market needs while preserving independent WEO decision-making.
Structured input on supplier risks, program gaps and assurance expectations.
Qualified representatives may participate in technical discussions and working groups.
Opportunity to contribute practical experience during initial program development.
Industry participation does not control recognition status, audit findings or individual decisions.
Governance & Assurance Model
WEO separates industry input, technical framework development and recognition decisions so the system remains relevant to real market needs while protecting impartiality.
WEO Life Sciences Public Registry
This registry is exclusively for WEO Life Sciences recognition. Search organizations and professionals whose approved scope includes GMPs, GDP or related Life Sciences activities.
Search recognized Certification & Assessment Bodies and other organizations with an approved Life Sciences scope.
Search individual professionals by surname or WEO ID. Competence Passport and Recognition Certificate links appear where available.
Recognition in practice
A body delivering voluntary GDP assessments applies for recognition for a defined pharmaceutical distribution or logistics scope. This is an illustrative pathway, not a recognition decision for a named organization.
Identify legal entities, activities, technical disciplines and the recognition scope requested.
Review organizational identity, existing authorizations where relevant, and eligibility under the selected program.
Governance and impartiality controls, qualified GDP auditors, assessment methods, sampled reports and decision records.
A decision-maker separate from the assessment reviews the evidence and records whether recognition is granted and for which scope.
If approved, the organization’s recognition record identifies the body category and the GDP assessment scope granted. It does not grant pharmaceutical distribution authorization.
Continuing review, corrective actions and renewal follow the applicable program. The agreed method and review frequency must be confirmed for that scope.
Founding Industry Members
For Founding Industry Council participation, technical collaboration, supplier-assurance pilots or general WEO Life Sciences inquiries, contact us directly.
admin@world-excellence.org